NASDAQ:CRVS - Corvus Pharmaceuticals Stock Price, Price Target & More

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Corvus Pharmaceuticals (NASDAQ:CRVS) posted its quarterly earnings results on Thursday, March, 1st. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.19. View Corvus Pharmaceuticals' Earnings History.

3 Wall Street analysts have issued 12-month price objectives for Corvus Pharmaceuticals' stock. Their forecasts range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Corvus Pharmaceuticals.

Corvus Pharmaceuticals saw a decrease in short interest during the month of March. As of March 15th, there was short interest totalling 873,065 shares, a decrease of 22.1% from the February 28th total of 1,120,698 shares. Based on an average daily trading volume, of 234,689 shares, the short-interest ratio is presently 3.7 days. Currently, 7.6% of the company's shares are short sold.

Some companies that are related to Corvus Pharmaceuticals include Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Mersana Therapeutics (MRSN), Cytokinetics (CYTK), Corium International (CORI), GTX (GTXI), Clearside Biomedical (CLSD), Dermira (DERM), Paratek Pharmaceuticals (PRTK), Strongbridge Biopharma (SBBP), Catalyst Biosciences (CBIO) and Merus (MRUS).

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

News stories about CRVS stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.04 on Accern's scale. They also gave news headlines about the company an impact score of 45.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Corvus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ORBIMED ADVISORS LLC (20.47%) and ADAMS STREET PARTNERS LLC (15.50%). Company insiders that own Corvus Pharmaceuticals stock include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CRVS stock can currently be purchased for approximately $10.56.

Corvus Pharmaceuticals has a market capitalization of $224.35 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]